Abbott Targets Amneal In Latest Fight Over Generic Niaspan

Law360, New York (August 31, 2012, 6:48 PM EDT) -- Abbott Laboratories' AbbVie Inc. on Thursday hit Amneal Pharmaceuticals LLC with a patent suit in Delaware federal court, arguing that Amneal has infringed a patent covering its cholesterol medication Niaspan.

AbbVie — which Abbott is scheduled to spin off as a stand-alone research-based pharmaceutical business later this year — along with another Abbott subsidiary Abbott Respiratory LLC maintain that Amneal has infringed its patent by way of an Abbreviated New Drug Application that Amneal submitted to the U.S. Food and Drug Administration seeking approval to make...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.